ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1788

The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis

Sungsin Jo1, Seung Hoon Lee1, Chanhyeok Jeon1, Sung Hoon Choi2, Ye-Soo Park3 and Tae-Hwan Kim4, 1Hanyang University Institute for Rheumatology Research, Seoul, South Korea, 2Hanyang University Seoul Hospital, Seoul, South Korea, 3Hanyang University College of Medicine, Guri, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Mouse Models, Other, osteoblast, TH17 Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Enthesitis is one of the most distinctive features and signs of ectopic bone formation in ankylosing spondylitis (AS). The Wnt/β-catenin pathway and Th17 cells are closely associated with pathological bone formation in AS, but their association has not been fully understood.

Methods: Twenty-five healthy control (HC) and seventy AS sera was subjected to ELISA for human TNF, IL-17A, and WNT5a. Ten PBMC (three HC and seven AS) and seven enthesis cells (three control- and four AS-enthesis) were conducted to RNA-sequencing. WNT5a and Receptor tyrosine kinase like orphan receptor 2 (ROR2) expression in enthesis were validated by immunohistochemistry analysis in five diseases control and seven AS patients. Next, overexpression or knockdown of ROR2 in primary enthesis was assessed bone-forming activity in the presence or absence of WNT5a treatment. Finally, enthesitis and ectopic bone formation at the ankle were evaluated in treatment with Ror2 mouse shRNA lentiviral particle in curdlan-injected SKG mice.

Results: TNF, IL-17A and Wnt5a in AS sera were significantly increased and positively correlated with mSASSS. Co-treatment with TNF and IL-17A dramatically increased WNT5a expression in AS-enthesis cells, as evaluated by RNA-sequencing, RT-qPCR, immunoblotting, and ELISA. Also, co-treatment with TNF and IL-17A augmented the bone-forming activity, bone-related gene expressions (ALP, RUNX2, and OCN), and WNT5A in AS-enthesis cells accompanied as compared to diseases control. Moreover, WNT5A treatment not only upregulated RUNX2 and CTCF expression in AS-enthesis cells via ROR2, but also showed excessive bone-forming activity under osteogenic stimulation. Intriguingly, an increase ROR2 expression in AS enthesis was revealed by RNA sequencing and validated at ectopic bone in spinal enthesis tissues from AS patients. Overexpression of ROR2 in enthesis had an accelerating bone-forming effect in Wnt5a treatment, whereas the knockdown of ROR2 in enthesis had shown the delaying bone-forming activity of AS enthesis in WNT5a treatment. Finally, treatment of Ror2 mouse shRNA lentiviral particle in curdlan-injected SKG mice exhibited a significant decrease in enthesitis and ectopic bone formation at the ankle.

Conclusion: We found that synergism of TNF and IL-17A triggers acceleration of bone mineralization and new bone formation in enthesis via WNT5/ROR2 axis. TNF&IL-17A/WNT5a/ROR2 axis may play a crucial role in pathological new bone formation in AS.

Supporting image 1

We found that co-treatment with TNF and IL_17A dramatically increased WNT5 expression in AS-enthesis.

Supporting image 2

We found that ROR2 is highly expressed in the ectopic bone of the human AS spinous process.


Disclosures: S. Jo: None; S. Lee: None; C. Jeon: None; S. Choi: None; Y. Park: None; T. Kim: None.

To cite this abstract in AMA style:

Jo S, Lee S, Jeon C, Choi S, Park Y, Kim T. The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-emerging-mechanism-of-tnfil-17a-wnt5a-ror2-axis-in-pathological-bone-formation-of-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-emerging-mechanism-of-tnfil-17a-wnt5a-ror2-axis-in-pathological-bone-formation-of-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology